‘Singapore is our home’, says UltraGreen.ai CEO after firm’s strong SGX debut

Key Concepts

• Ultra Green.ai: A Singapore-based medtech firm specializing in high-precision surgical tools and an AI-powered platform for real-time data analysis during procedures.
• SGX (Singapore Exchange): The stock exchange where Ultra Green.ai debuted.
• IPO (Initial Public Offering): The process by which a private company becomes public by selling shares to investors.
• ICG (Indocyanine Green): A fluorescent dye used in surgical procedures to visualize blood flow and tissues.
• AI (Artificial Intelligence): Used by Ultra Green.ai to analyze surgical data for improved decision-making.
• Medtech: Medical technology sector.
• Dual Listing: Listing a company's shares on more than one stock exchange.
• NASDAQ: A major stock exchange, often associated with technology companies.

Ultra Green.ai's SGX Debut and Market Performance

Ultra Green.ai, a Singapore-based medtech firm, has successfully debuted on the main board of the SGX. The company's shares are trading up by 8.28% at $1.57, a notable increase from its IPO price of approximately $1.45 per share. This debut involved a float of about 112 million shares. The market reaction has been positive, with shares opening around the US $1.60 level, representing a 10% jump from the IPO offer price. This strong initial performance is generally considered a positive indicator. Trading volume has also been relatively high, with over 15 million shares changing hands. Analysts had anticipated a strong performance from the outset, aligning with the company's significant IPO fundraising aim of US $400 million.

Company Profile and Value Proposition

Ultra Green.ai develops high-precision surgical tools and is building an AI-powered platform to analyze real-time data during surgical procedures. The company positions itself as both a "value and a growth play."

• Value Proposition: As the global population ages, the demand for surgeries is expected to increase, directly benefiting Ultra Green.ai's product usage. A key aspect of their value proposition is the cost-effectiveness of their solutions. While many surgeries enabled by their technology cost thousands of dollars, their product cost is around US $200. This cost advantage, coupled with the growing number of surgeries, is projected to drive business growth.
• AI Integration: The company is attaching an AI platform to quantify data, providing surgeons and robots with enhanced tools for precision surgery. This integration of data analysis and AI is a unique characteristic of their offering. The company's name, "Ultra Green," is derived from their process of using blood, turning it green (referring to the ICG dye), and applying AI.

Expansion Strategy and Focus on Asia

Ultra Green.ai has a strategic focus on expansion in Asia, with Singapore serving as its home base.

• Credibility and Local Presence: Being based in Singapore provides credibility from a local perspective. The CEO, Ravendo Sachan, is a Permanent Resident in Singapore, and the family office is Singapore-owned, reinforcing their commitment to the region.
• Asian Market Opportunity: The company identifies significant growth segments in Asia. Their strategy for this region is to overcome capital expenditure limitations.
  • Challenge in Asia: The high cost of camera systems required for visualizing ICG dye in the human body (ranging from US $200,000 to half a million dollars) has historically limited ICG growth in Asia. These systems are typically used in surgical theaters.
  • Ultra Green.ai's Solution: To address this, Ultra Green.ai has developed its own extremely low-cost camera device. This allows them to offer their ICG product "literally for free," facilitating adoption and allowing users to experience the clinical benefits. This approach aims to bring down capital expenditure and enable operations outside of traditional surgical theaters, in smaller clinics.
• Phased Listing Approach: The company plans to focus on the SGX for now to establish a credible name in the Asian market. While a NASDAQ listing is a possibility in the long run, it will be considered when it offers meaningful value, particularly given NASDAQ's tech-heavy nature and the need for substantial data and AI presence. Ultra Green.ai is flexible regarding future listings as they have sufficient cash flow to fund their business growth without immediate need for further capital raises.

Technical Details of Ultra Green.ai's Technology

The core of Ultra Green.ai's offering lies in high-precision surgical tools, specifically focusing on fluorescence imaging and Indocyanine Green (ICG) dyes.

• ICG Dyes: These dyes are injected into a patient's bloodstream during surgical procedures.
• Infrared Light Camera: With the aid of a specialized infrared light camera, surgeons can visualize blood flow, tissues, and even tumors in real-time.
• AI-Powered Platform: This platform analyzes the real-time data generated during procedures, assisting in decision-making.
• Benefits: The combined technology aims to enhance surgical precision and reduce the risk of complications for patients.

Singapore's Capital Markets and IPO Momentum

Ultra Green.ai's listing is significant as it is the largest non-REIT listing on the SGX in years. This debut signals positive momentum in Singapore's capital markets.

• Strong IPO Year for SGX: Singapore has experienced a robust year for IPOs, with 13 companies, including Ultra Green.ai, having listed on the SGX this year. The SGX anticipates at least 30 more firms in the pipeline.
• Global Ranking: According to a Bloomberg ranking of IPO venues, Singapore is positioned in ninth place globally, surpassing cities like London.
• Post-IPO Proceeds: Singapore is leading Southeast Asia in terms of post-IPO proceeds, having raised approximately US $1.66 billion so far this year. This figure is largely attributed to two major Real Estate Investment Trust (REIT) listings: NTUC and Centurion Accommodation, each raising about US $500 million, accounting for 88% of the total funds raised.
• SGX-NASDAQ Partnership: The SGX has recently announced a partnership with NASDAQ to facilitate dual listings. This collaboration will streamline the process for companies by requiring only one set of offering documents, which is expected to further bolster the positive momentum in the local stock market.

Conclusion

Ultra Green.ai's successful debut on the SGX highlights the growing strength of Singapore's capital markets and the increasing investor interest in the medtech sector. The company's innovative approach to precision surgery, combining cost-effective ICG dyes with an AI-powered platform, positions it for significant growth, particularly in the Asian market. Their strategic focus on Singapore as a base and their phased approach to international listings demonstrate a well-thought-out expansion plan. The SGX's partnership with NASDAQ is poised to further enhance its attractiveness as an IPO venue, supporting the continued momentum of new listings.